Stifel Initiates Coverage On Mirum Pharmaceuticals with Buy Rating, Announces Price Target of $48
Portfolio Pulse from Benzinga Newsdesk
Stifel analyst Dae Gon Ha initiates coverage on Mirum Pharmaceuticals (NASDAQ:MIRM) with a Buy rating and a price target of $48.

April 17, 2024 | 11:14 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Stifel analyst Dae Gon Ha has initiated coverage on Mirum Pharmaceuticals with a Buy rating and set a price target of $48.
The initiation of coverage by Stifel with a Buy rating and a significant price target suggests a strong bullish outlook for Mirum Pharmaceuticals. This endorsement from a reputable analyst is likely to instill confidence in investors, potentially driving up the stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100